Literature DB >> 14661933

Solubilization of cationic drugs in lung surfactant.

Xiangmin Liao1, Timothy S Wiedmann.   

Abstract

PURPOSE: The association of hydrophobic, cationic drugs with lung surfactant was determined to assess the pharmacokinetic implications on drug disposition and retention in the lung.
METHODS: The distribution coefficients, K, were determined at 25 and 37 degrees in normal saline solution buffered at pH 7.4 for a series of structurally related, cationic drugs. Drugs were dispersed into lung surfactant, equilibrated, and then centrifuged to separate the aqueous phase from the surfactant pellet. Drug concentrations in the supernatant and pellet were determined following dilution using spectrophotometric assays. In addition, the apparent acid dissociation constant of quinacrine in the presence and absence of surfactant was determined by measuring the pH-dependent absorption spectra. The effect of stereochemistry on the distribution of drugs into surfactant was examined with (R)- and (S)-propranolol.
RESULTS: The mole fraction distribution coefficients for amitriptyline, promethazine, promazine, ethopropazine, imipramine, R-propranolol, and S-propranolol at 25 degrees C were 6,560 +/- 500, 28,400 +/- 1,500, 12,100 +/- 840, 5,480 +/- 330, 4,490 +/- 250, 8,680 +/- 260, 8,190 +/- 530, respectively. At 37 degrees C, the distribution coefficients were generally smaller indicating a significant exothermic heat of transfer for these solutes from aqueous solution to the lung surfactant. The pKa of quinacrine was 7.43 +/- 0.04 in aqueous solution and was shifted to 7.62 +/- 0.06 in the presence of lung surfactant. From this shift, the double layer potential for quinacrine-lung surfactant was estimated to be -0.012 V assuming a dielectric constant equivalent to that of water.
CONCLUSIONS: Cationic drugs have very favorable distributions from an aqueous solution to the lipid phase of lung surfactant. The transfer process generally has both a large entropic and enthalpic contribution. The latter thermodynamic aspect may be related to the charge interaction between the solute and the negatively charged surfactant. Finally, no significant effect of stereochemistry was evident with the distribution of (R)- and (S)-propranolol.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14661933     DOI: 10.1023/b:pham.0000003386.33834.cd

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  10 in total

Review 1.  Kinetic aspects of drug disposition in the lungs.

Authors:  R N Upton; D J Doolette
Journal:  Clin Exp Pharmacol Physiol       Date:  1999 May-Jun       Impact factor: 2.557

2.  Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.

Authors:  S Pham; T S Wiedmann
Journal:  J Pharm Sci       Date:  2001-01       Impact factor: 3.534

3.  Fourier-transform infrared spectroscopy studies of lipid/protein interaction in pulmonary surfactant.

Authors:  K E Reilly; A J Mautone; R Mendelsohn
Journal:  Biochemistry       Date:  1989-09-05       Impact factor: 3.162

4.  Disposition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in bile duct-cannulated rats: stereoselective metabolism and tissue distribution.

Authors:  Zheng Wu; Pramod Upadhyaya; Steven G Carmella; Stephen S Hecht; Cheryl L Zimmerman
Journal:  Carcinogenesis       Date:  2002-01       Impact factor: 4.944

5.  Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model.

Authors:  G Hochhaus; H Möllmann; H Derendorf; R J Gonzalez-Rothi
Journal:  J Clin Pharmacol       Date:  1997-10       Impact factor: 3.126

6.  Effect of dose and release rate on pulmonary targeting of liposomal triamcinolone acetonide phosphate.

Authors:  S Suarez; R J Gonzalez-Rothi; H Schreier; G Hochhaus
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

7.  Paraquat accumulation: tissue and species specificity.

Authors:  M S Rose; E A Lock; L L Smith; I Wyatt
Journal:  Biochem Pharmacol       Date:  1976-02-15       Impact factor: 5.858

8.  Drug solubilization in lung surfactant.

Authors:  T S Wiedmann; R Bhatia; L W Wattenberg
Journal:  J Control Release       Date:  2000-03-01       Impact factor: 9.776

9.  Pulmonary targeting of liposomal triamcinolone acetonide phosphate.

Authors:  R J Gonzalez-Rothi; S Suarez; G Hochhaus; H Schreier; A Lukyanov; H Derendorf; T D Costa
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

10.  Effects of solvent polarity on the acid dissociation constants of benzoic acids.

Authors:  J T Rubino; W S Berryhill
Journal:  J Pharm Sci       Date:  1986-02       Impact factor: 3.534

  10 in total
  3 in total

1.  Toxicity of orally inhaled drug formulations at the alveolar barrier: parameters for initial biological screening.

Authors:  Eleonore Fröhlich
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 2.  Inhaled nano- and microparticles for drug delivery.

Authors:  Ibrahim M El-Sherbiny; Nancy M El-Baz; Magdi H Yacoub
Journal:  Glob Cardiol Sci Pract       Date:  2015-03-31

3.  A Biocompatible Synthetic Lung Fluid Based on Human Respiratory Tract Lining Fluid Composition.

Authors:  Abhinav Kumar; Wachirun Terakosolphan; Mireille Hassoun; Kalliopi-Kelli Vandera; Astrid Novicky; Richard Harvey; Paul G Royall; Elif Melis Bicer; Jonny Eriksson; Katarina Edwards; Dirk Valkenborg; Inge Nelissen; Dave Hassall; Ian S Mudway; Ben Forbes
Journal:  Pharm Res       Date:  2017-05-30       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.